Monthly Archives: November 2018

Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on preliminary feedback from the Type C meeting held with the U.S. Food and

By |2018-11-01T22:04:05+00:00November 1st, 2018|Biologics, Regulatory|

United Orthopedic Corporation Announces UTS™ Hip Stem and an Extension of its U-Motion II™ Acetabular System Are Now Available

IRVINE, Calif., Nov. 1, 2018 /PRNewswire/ -- United Orthopedic Corporation, a leading international designer, manufacturer, and distributor of innovative orthopedic implants and instruments, today announced that the UTS™ (United Tri-tapered Short Stem) hip stem and an extension of the U-Motion II™ Acetabular System are now available to surgeons in the U.S. "The UTS hip stem and U-Motion II extension reflect

By |2018-11-01T20:31:00+00:00November 1st, 2018|Recon|

RTI Surgical® Announces Third Quarter 2018 Results

November 01, 2018 ALACHUA, Fla.--(BUSINESS WIRE)--RTI Surgical, Inc. (Nasdaq: RTIX), a global surgical implant company, reported operating results for the third quarter of 2018. “The strength of our third quarter results underscores the substantial ongoing progress we are making across our strategic transformation and the growing momentum throughout the company,” stated Camille Farhat, President and

By |2018-11-01T17:14:50+00:00November 1st, 2018|Financial|

Medacta Unveils Two New Kinematic Alignment Options for Knee Replacement Surgery

November 01, 2018 CASTEL SAN PIETRO, Switzerland & DALLAS--(BUSINESS WIRE)--Medacta International, the privately held, family-owned global leader in the design of innovative joint replacement and spinal surgery products, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for the GMK® Sphere – Kinematic Alignment instrumentation and surgical technique for total knee

By |2018-11-01T16:54:39+00:00November 1st, 2018|Recon, Regulatory|

DJO® Announces Industry-First Risk Assessment Tool To Confirm Outpatient Joint Replacement Pathways

November 01, 2018 DALLAS--(BUSINESS WIRE)--DJO, a leading provider of medical technologies designed to get and keep people moving, announced today the availability of the industry’s first Outpatient Arthroplasty Risk Assessment tool, the OaraScore™. The easy-to-use software tool provides medical professionals with the information needed to assess the appropriate post-operative length of stay after total joint arthroplasty (TJA). The

By |2018-11-01T16:23:51+00:00November 1st, 2018|Recon|

DJO® Unveils Two Additional Products, Further Expanding the Breadth of the EMPOWR Knee System®

November 01, 2018 DALLAS--(BUSINESS WIRE)--DJO, a leading provider of medical technologies designed to get and keep people moving, introduced the EMPOWR Porous™ Knee System and EMPOWR™ Complex Primary Knee System at the 2018 Annual Meeting of the American Association of Hip and Knee Surgeons (AAHKS) today (Booth # 510). These new additions to the EMPOWR™ Knee Platform expand one of the

By |2018-11-01T15:59:12+00:00November 1st, 2018|Recon, Top Stories|

Zimmer Biomet Appoints Ivan Tornos as Group President, Orthopedics

WARSAW, Ind., October 31, 2018 – Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced Ivan Tornos, previously Worldwide President for Urology/Medical and Critical Care at Becton, Dickinson and Company (NYSE: BDX), will join Zimmer Biomet as Group President, Orthopedics, effective November 1, 2018. “Ivan is a great addition

By |2018-11-01T15:29:40+00:00November 1st, 2018|Extremities|

BONESUPPORT HOLDING AB (publ) – Q3 2018 Interim Report – invitation to conference call and webcast

Lund, Sweden, 08.00 CET, 1 November 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids will publish its Q3 2018 Interim Report on Wednesday 7 November 2018 at 8am CET. The Company will hold a conference call and an online presentation on the same day at 10am CET. The call will be hosted by Emil Billbäck, CEO and Björn

By |2018-11-01T15:17:19+00:00November 1st, 2018|Financial|